Lv1
100 积分 2024-12-21 加入
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
11小时前
已完结
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
11天前
已完结
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
2个月前
已完结
Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia
2个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
2个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
Choosing the Optimal Non-Statin Lipid Lowering Therapies for Statin-Intolerant Patients: A Systematic Review and Network Meta-Analysis
2个月前
已完结
Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy
2个月前
已完结
皖公网安备34019202002308
